Abstract:Continuous cultivation of mammalian cells originated in chemostats in the 1950s and, through a series of technological advancements, has evolved into modern-day high-density perfusion processes with volumetric productivities >5 g L-1 day(-1) over extended cultivation periods. With appropriate process development, these productivities can be achieved with no adverse impact on cell line stability and product quality. Developments in downstream processing and automation have enabled the integration of drug substance manufacturing processes suitable for next-generation plants that require lower capital deployment, with the potential for rapid construction and validation for clinical and commercial production. Perfusion also has been successfully used to generate high-density cell banks (> 50 x 10(6) cells mL(-1)) and for seed-train optimization. They have resulted in significant productivity increases (10-fold increase in volumetric productivity) from fed-batch bioreactors by providing a high-density seeding culture that elevates the inoculation density in a production bioreactor (> 5 x 10(6) cells mL(-1)). Related advancements in cell culture medium formulations and cell line performance typically are independent of bioreactor format and have broad applicability for biotherapeutic manufacturing. The last decade has seen renewed interest in high-density perfusion cultures and technological advances spanning the entire space of drug substance manufacturing - from cell line development to the final purification step. Continually evolving, these new technologies now are being introduced into clinical and commercial manufacturing. We anticipate that the general principles and knowledge gleaned from process intensification will extend well beyond classical perfusion cultivation and into all aspects of mammalian cell culture. (c) 2021 Society of Chemical Industry (SCI).

Disposable rocking bioreactors: recent applications and progressive perspectives

Mass transfer characteristics in disposable rocking bioreactors: A critical review and quantitative data catalogue

Innovative fixed bed bioreactor platform: Enabling linearly scalable adherent cell biomanufacturing with real-time biomass prediction from nutrient consumption

A paradigm shift for biocatalytic microreactors: Decoupling application from reactor design

Wall‐Immobilized Biocatalyst Vs. Packed Bed In Miniaturized Continuous Reactors: Performances And Scale‐Up

Towards Self-Regulated Bioprocessing: A Compact Benchtop Bioreactor System for Monitored and Controlled 3D Cell and Tissue Culture

Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies

Microbioreactors for Process Development and Cell-Based Screening Studies

Bioreactor engineering using disposable technology for enhanced production of hCTLA4Ig in transgenic rice cell cultures

Cultivation and Differentiation of Encapsulated hMSC-TERT in a Disposable Small-Scale Syringe-Like Fixed Bed Reactor

Reactor Selection for Effective Continuous Biocatalytic Production of Pharmaceuticals

Progress in biocatalysis with immobilized viable whole cells: systems development, reaction engineering and applications

An Integrated Approach toward the Biomanufacturing of Engineered Cell Therapy Products in a Stirred-Suspension Bioreactor

Cell-Free Synthesis: Expediting Biomanufacturing of Chemical and Biological Molecules

On demand biomanufacturing through synthetic biology approach

Advances in bioprocessing for efficient bio manufacture

From Chemostats to High-Density Perfusion: the Progression of Continuous Mammalian Cell Cultivation

Design and evaluation of a 3D‐printed, lab‐scale perfusion bioreactor for novel biotechnological applications

Extending the application of biocatalysis to meet the challenges of drug development

Microbioreactor for lower cost and faster optimisation of protein production

Microfluidic Devices as Process Development Tools for Cellular Therapy Manufacturing